All HHS Contracts — March 26, 2026

Three contracts total $793M obligated (potential $1.2B with options), with 2/3 from BARDA emphasizing biotech/COVID, delivering revenue certainty for awardees.

Single largest award provides 64% of period value and $455M option upside to 2028, underscoring tobacco/health assessment priority.

Minimal spending ($240K on $161M ATI; $23M on $126M PPD) vs. Westat's $213M highlights potential delays in BARDA projects.

Long tenors (2027-2029) and low initial outlays expose to funding cliffs and cost overruns, especially firm-fixed-price (ATI) and T&M (PPD) structures.

COVID-focused PPD work ($126M) vulnerable if pandemic priorities wane; PATH tobacco study tied to public health policy shifts.

$455M Westat options + full BARDA obligations offer $664M upside if exercised, favoring corporate providers.

BARDA's $287M biotech/COVID R&D signals follow-on potential in immunogenicity/vaccine tech amid ongoing health threats.

BARDA awards comprise 36% of value ($287M) for COVID/biotech R&D to 2029, contrasting NIH's PATH focus.

All contracts extend 2-4 years with $793M+ committed, dominated by non-small biz corporates.

{"entity"=>"Westat, Inc.", "reason"=>"$505M obligation (potential $960M) anchors 64% of HHS stream value through 2028.", "trigger"=>"Option exercises >$200M or outlays exceeding $300M"}

{"entity"=>"PPD Development LP", "reason"=>"$126M BARDA COVID R&D to 2029 with $23M outlaid offers extension upside.", "trigger"=>"Increased outlays or new immunogenicity contracts"}

{"entity"=>"BARDA biotech pipeline", "reason"=>"36% of awards signal follow-on potential post-$287M commitments.", "trigger"=>"Next task orders >$100M"}